These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 36543346)

  • 21. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
    Jia P; Zhu Y; Zhang H; Cheng B; Guo P; Xu Y; Yang Q
    BMC Microbiol; 2022 Oct; 22(1):234. PubMed ID: 36182895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients.
    Barbier F; Hraiech S; Kernéis S; Veluppillai N; Pajot O; Poissy J; Roux D; Zahar JR;
    Ann Intensive Care; 2023 Jul; 13(1):65. PubMed ID: 37462830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria.
    Pintado V; Ruiz-Garbajosa P; Aguilera-Alonso D; Baquero-Artigao F; Bou G; Cantón R; Grau S; Gutiérrez-Gutiérrez B; Larrosa N; Machuca I; Martínez Martínez L; Montero MM; Morte-Romea E; Oliver A; Paño-Pardo JR; Sorlí L
    Enferm Infecc Microbiol Clin (Engl Ed); 2023; 41(6):360-370. PubMed ID: 36522272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
    Mansour H; Ouweini AEL; Chahine EB; Karaoui LR
    Am J Health Syst Pharm; 2021 Mar; 78(8):674-683. PubMed ID: 33580649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
    Scudeller L; Righi E; Chiamenti M; Bragantini D; Menchinelli G; Cattaneo P; Giske CG; Lodise T; Sanguinetti M; Piddock LJV; Franceschi F; Ellis S; Carrara E; Savoldi A; Tacconelli E
    Int J Antimicrob Agents; 2021 May; 57(5):106344. PubMed ID: 33857539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019.
    Jean SS; Lu MC; Ho MW; Ko WC; Hsueh PR;
    Int J Antimicrob Agents; 2022 Mar; 59(3):106521. PubMed ID: 35066144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia.
    Bassetti M; Mularoni A; Giacobbe DR; Castaldo N; Vena A
    Semin Respir Crit Care Med; 2022 Apr; 43(2):280-294. PubMed ID: 35088403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
    Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
    J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenotypic characterization of carbapenem non-susceptible gram-negative bacilli isolated from clinical specimens.
    Abdeta A; Bitew A; Fentaw S; Tsige E; Assefa D; Lejisa T; Kefyalew Y; Tigabu E; Evans M
    PLoS One; 2021; 16(12):e0256556. PubMed ID: 34855767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
    J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship.
    Jean SS; Gould IM; Lee WS; Hsueh PR;
    Drugs; 2019 May; 79(7):705-714. PubMed ID: 30972660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.
    Doi Y
    Clin Infect Dis; 2019 Nov; 69(Suppl 7):S565-S575. PubMed ID: 31724043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).
    Sader HS; Flamm RK; Carvalhaes CG; Castanheira M
    Diagn Microbiol Infect Dis; 2020 Mar; 96(3):114833. PubMed ID: 31924426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.
    Karaiskos I; Giamarellou H
    Expert Opin Pharmacother; 2014 Jul; 15(10):1351-70. PubMed ID: 24766095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales.
    Kaye KS; Naas T; Pogue JM; Rossolini GM
    Infect Dis Ther; 2023 Mar; 12(3):777-806. PubMed ID: 36847998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol and comparators against Gram-negative organisms causing bloodstream infections in Northern Italy (2019-2021): emergence of complex resistance phenotypes.
    Bianco G; Boattini M; Comini S; Iannaccone M; Casale R; Allizond V; Barbui AM; Banche G; Cavallo R; Costa C
    J Chemother; 2022 Sep; 34(5):302-310. PubMed ID: 35098907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
    J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
    Karlowsky JA; Lob SH; Raddatz J; DePestel DD; Young K; Motyl MR; Sahm DF
    Clin Infect Dis; 2021 Jun; 72(12):2112-2120. PubMed ID: 32246147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
    Tamma PD; Hsu AJ
    J Pediatric Infect Dis Soc; 2019 Jul; 8(3):251-260. PubMed ID: 30793757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.